Bioadaptives (BDPT) Gross Profit (2016 - 2026)

Bioadaptives has disclosed Gross Profit across 9 years of filings, most recently posting $4113.0 for Q1 2026.

• Gross Profit for Q1 2026 came in at $4113.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $16610.0 (up 3771.79% YoY), and the FY2025 annual result was $12497.0, up 210.1% from the prior year.
• Gross Profit came in at $4113.0 for Q1 2026 at Bioadaptives, down from $7583.0 in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $7583.0 in Q4 2025 to a low of $429.0 in Q2 2024.
• The 5-year median for Gross Profit is $2076.5 (2022), against an average of $2756.1.
• Across the five-year window, Gross Profit surged 162.04% in 2023 and tumbled 71.21% in 2024, its largest moves.
• Bioadaptives' Gross Profit stood at $1030.0 in 2022, then jumped by 162.04% to $2699.0 in 2023, then slumped by 84.11% to $429.0 in 2024, then soared by 1667.6% to $7583.0 in 2025, then sank by 45.76% to $4113.0 in 2026.
• The last three Gross Profit figures came in at $4113.0 (Q1 2026), $7583.0 (Q4 2025), and $3851.0 (Q3 2025), per Business Quant data.